- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
- 180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
- 180 Life Sciences Announces Review of Strategic Alternatives
- 180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
- 180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
- 180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
- 180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
- 180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
More ▼
Key statistics
As of last trade, 180 Life Sciences Corp (ATNF:NAQ) traded at 1.76, 32.33% above the 52 week low of 1.33 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.87 |
---|---|
High | 1.87 |
Low | 1.53 |
Bid | 1.75 |
Offer | 1.83 |
Previous close | 1.53 |
Average volume | 36.23k |
---|---|
Shares outstanding | 941.59k |
Free float | 913.00k |
P/E (TTM) | -- |
Market cap | 1.44m USD |
EPS (TTM) | -41.54 USD |
Data delayed at least 15 minutes, as of May 21 2024 18:11 BST.
More ▼